SMAD3 and acute kidney injury: We next tested our hypothesis that targeting Smad3 may be a novel therapy for SARS‐CoV‐2 N protein‐induced AKI, which was examined in SARS‐CoV‐2 N‐induced AKI mice by a daily intraperitoneal (i.p.)injection with a Smad3 inhibitor SIS3.